Recommended

New webinar: Overcoming critical challenges in AI-driven drug discovery
Watch on demand: Rapid cell-based profiling of multi-target anti-obesity drugs Watch here!
Download now: Unlock the power of stem cell therapy and discover the potential for new therapies for primary open-angle glaucoma
Brand new Beyond the Lab report on antibodies… Download NOW!
article

Expert view: Measuring protein interactions in blood – not as trivial as it sounds

Posted: 11 September 2020 | | No comments yet

In the continuing battle against COVID-19, researchers now must identify the best candidates for vaccines and convalescent serum therapies against the virus.

This is more difficult than it sounds and will require researchers to employ new techniques that are not based on decades-old technologies. At the heart of this challenge is the accurate identification of neutralising antibodies – proteins that bind to the SARS-CoV-2 spike protein, thereby halting entry of the virus into cells.

    To read this expert view in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of Fluidic Analytics

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.